BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23134857)

  • 21. Peripheral blood lymphocyte and monocyte recovery and survival in acute leukemia postmyeloablative allogeneic hematopoietic stem cell transplant.
    Thoma MD; Huneke TJ; DeCook LJ; Johnson ND; Wiegand RA; Litzow MR; Hogan WJ; Porrata LF; Holtan SG
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):600-7. PubMed ID: 21843495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of pretransplantation serum ferritin on nonrelapse mortality after myeloablative and nonmyeloablative allogeneic hematopoietic stem cell transplantation.
    Kataoka K; Nannya Y; Hangaishi A; Imai Y; Chiba S; Takahashi T; Kurokawa M
    Biol Blood Marrow Transplant; 2009 Feb; 15(2):195-204. PubMed ID: 19167679
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin.
    Yu ZP; Ding JH; Wu F; Liu J; Wang J; Cheng J; Zhao G
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):593-9. PubMed ID: 21846461
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation--investigation of potential limitations of the index.
    Birninger N; Bornhäuser M; Schaich M; Ehninger G; Schetelig J
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1822-32. PubMed ID: 21708108
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Haploidentical/mismatched hematopoietic stem cell transplantation without in vitro T cell depletion for T cell acute lymphoblastic leukemia.
    Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Zhang XH; Huang XJ
    Biol Blood Marrow Transplant; 2012 May; 18(5):716-21. PubMed ID: 21924223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conventional versus reduced-intensity conditioning regimen for allogeneic stem cell transplantation in patients with hematological malignancies.
    Valcárcel D; Martino R; Sureda A; Canals C; Altés A; Briones J; Sanz MA; Parody R; Constans M; Villela SL; Brunet S; Sierra J
    Eur J Haematol; 2005 Feb; 74(2):144-51. PubMed ID: 15654906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation.
    Tan Y; Du K; Luo Y; Shi J; Cao L; Zheng Y; Zheng G; Zhao Y; Ye X; Cai Z; Huang H
    Transfusion; 2014 Jun; 54(6):1493-500. PubMed ID: 24372162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study.
    Itonaga H; Iwanaga M; Aoki K; Aoki J; Ishiyama K; Ishikawa T; Sakura T; Fukuda T; Najima Y; Yujiri T; Mori T; Kurokawa M; Nawa Y; Uchida N; Morishita Y; Hashimoto H; Eto T; Hirokawa M; Morishima Y; Nagamura-Inoue T; Atsuta Y; Miyazaki Y
    Leuk Res; 2016 Feb; 41():48-55. PubMed ID: 26754557
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire.
    Park S; Labopin M; Yakoub-Agha I; Delaunay J; Dhedin N; Deconinck E; Michallet M; Robin M; De Revel T; Bernard M; Vey N; Lioure B; Lapusan S; Tabrizi R; Bourhis JH; Huynh A; Beguin Y; Socié G; Dreyfus F; Fenaux P; Mohty M
    Eur J Haematol; 2013 May; 90(5):355-64. PubMed ID: 23320648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Leukemia lineage-specific chimerism analysis and molecular monitoring improve outcome of donor lymphocyte infusions.
    Sairafi D; Remberger M; Uhlin M; Ljungman P; Ringdén O; Mattsson J
    Biol Blood Marrow Transplant; 2010 Dec; 16(12):1728-37. PubMed ID: 20542125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison.
    Wang Y; Liu DH; Xu LP; Liu KY; Chen H; Chen YH; Han W; Shi HX; Huang XJ
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):821-30. PubMed ID: 20831895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic efficacy of allogeneic hematopoietic stem cell transplantation in children with chronic myelogenous leukemia].
    Jiang H; Hu WT; Chen J; Luo CY; Wang JM; Zhou M; Ye QD; Tang YJ; Luo CJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Jan; 15(1):19-24. PubMed ID: 23336162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
    Lin Q; Dong M; Wang QM; Wen JY; Wu XY
    Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Allo-HSCT for acute leukemia of ambiguous lineage in adults: the comparison between standard conditioning and intensified conditioning regimens.
    Liu QF; Fan ZP; Wu MQ; Sun J; Wu XL; Xu D; Jiang QL; Zhang Y; Huang F; Wei YQ; Zhao J; Yu GP; Meng FY
    Ann Hematol; 2013 May; 92(5):679-87. PubMed ID: 23274355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Analysis of risk factors for the development of acute graft-versus-host disease in 151 cases of allo-hematopoietic stem cell transplantation].
    Chen Y; Lu DP; Liu KY; Dong LJ; Ren HY; Huang XJ; Chen H; Liu DH; Jiang Q; Chen YH; Xu LP; Zhang YC; Lu J; Gao ZY
    Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):74-7. PubMed ID: 15921621
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center.
    Wang Y; Liu DH; Liu KY; Xu LP; Zhang XH; Han W; Chen H; Chen YH; Wang FR; Wang JZ; Sun YQ; Huang XJ
    Cancer; 2013 Mar; 119(5):978-85. PubMed ID: 23097265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Induction of aGVHD after allogeneic hematopoietic stem cell transplantation for refractory or relapsed acute leukemia].
    Sun J; Meng FY; Liu QF; Xu D; Xu B; Liu XL
    Ai Zheng; 2003 Dec; 22(12):1321-4. PubMed ID: 14693060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.